<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397358</url>
  </required_header>
  <id_info>
    <org_study_id>31656</org_study_id>
    <nct_id>NCT00397358</nct_id>
  </id_info>
  <brief_title>Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients</brief_title>
  <official_title>Open-label Study to Evaluate the Effects of Once Daily Extraneal (7.5% Icodextrin) Peritoneal Dialysis Solution on Triglyceride Levels in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, open label, multi-center study evaluates the use of 7.5% icodextrin used in
      the long-dwell exchange in peritoneal dialysis patients with elevated triglyceride levels.
      Fasting triglyceride levels will be measured during the study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date type="Actual">November 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting triglyceride levels.</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <condition>Hypertriglyceridemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  CAPD/APD on dialysis for at least 3 months

          -  Elevated fasting triglyceride levels

        Exclusion Criteria:

          -  enrolled in another study requiring IRB approval

          -  allergy to starch-based polymers

          -  glycogen storage disease

          -  maltose or isomaltose intolerance

          -  active alcohol/substance abuse

          -  Pregnant or nursing

          -  received an investigational drug within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter Healthcare Corporation</last_name>
    <role>Study Director</role>
    <affiliation>Call central contact for information</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Santa Clara - Homestead</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Specialists</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysis Center of Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int. 2000;20 Suppl 2:S37-41. Review.</citation>
    <PMID>10911641</PMID>
  </reference>
  <reference>
    <citation>Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001 May-Jun;21(3):275-81.</citation>
    <PMID>11475343</PMID>
  </reference>
  <reference>
    <citation>Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif. 2005;23(4):303-10. Epub 2005 Jun 23.</citation>
    <PMID>15980620</PMID>
  </reference>
  <reference>
    <citation>Kronenberg F, Lingenhel A, Neyer U, Lhotta K, KÃ¶nig P, Auinger M, Wiesholzer M, Andersson H, Dieplinger H. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl. 2003 May;(84):S113-6.</citation>
    <PMID>12694323</PMID>
  </reference>
  <reference>
    <citation>Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2001;17:80-3.</citation>
    <PMID>11510303</PMID>
  </reference>
  <reference>
    <citation>Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant. 2006 Feb;21(2):494-8. Epub 2005 Oct 12.</citation>
    <PMID>16221697</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Extraneal(7.5% icodextrin)Peritoneal Dialysis Solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

